Chimeric antigen receptor T cells targeting cell surface GRP78 efficiently kill glioblastoma and cancer stem cells

BACKGROUND: Glioblastoma (GBM) is recognized as among the most aggressive forms of brain tumor. Patients typically present with a five-year survival rate of less than 6% with traditional surgery and chemoradiotherapy, which calls for novel immunotherapies like chimeric antigen receptor T (CAR-T) cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shijie, Wei, Wenwen, Yuan, Yuncang, Sun, Bin, Yang, Dong, Liu, Nan, Zhao, Xudong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362566/
https://www.ncbi.nlm.nih.gov/pubmed/37481592
http://dx.doi.org/10.1186/s12967-023-04330-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362566/
https://www.ncbi.nlm.nih.gov/pubmed/37481592
http://dx.doi.org/10.1186/s12967-023-04330-0

Ejemplares similares